Navigation Links
California Healthcare Institute Announces Executive Promotion

LA JOLLA, Calif. (PRWEB) April 22, 2013

The California Healthcare Institute (CHI) announced today the promotion of Holly Frisque, SPHR, to vice president of administration. Frisque, who has been with CHI since 2009, previously served as senior director of operations. CHI is a non-profit public policy research and advocacy organization for California’s biomedical R&D industry.

As vice president of administration, Frisque leads CHI in supervision of the human resources, communications, marketing, finance, membership services, corporate compliance and technology departments.

“For over four years, Holly’s leadership has contributed immensely to the positive direction and growth of CHI. This hard-earned promotion reflects CHI’s commitment to providing the highest level of member service and organizational management,” said CHI President and CEO David L. Gollaher, Ph.D. “Her diligence and professionalism will continue to make CHI a team-oriented and effective biomedical advocacy organization on behalf of our members.”

Frisque joined CHI as office manager of the La Jolla headquarters before being promoted to senior director of operations in 2012. Before joining CHI, Frisque served as the director of administration at Gizmo5 Technologies, Inc. and Linspire, Inc., two software development companies in San Diego. She also led administration for the biotech investment division of Enterprise Partners Venture Capital. Frisque has achieved the Senior Professional in Human Resources designation, reflecting her expertise in strategic management and highlighting her commitment to best practices. Frisque holds a bachelor's degree in psychology and a minor in creative writing from University of California, Riverside.

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
2. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
3. Executives from Johnson & Johnson, GlaxoSmithKline and California State Board of Pharmacy discuss pharmaceutical packaging challenges at Pharmapack North America 2013
4. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
5. California Healthcare Institute Appoints Vice President-State Government Affairs
6. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
7. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
8. JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte
9. The California Healthcare Institute Responds to New Efforts to Repeal the Federal Medical Device Excise Tax
10. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
11. Precision Coating to Showcase Next Generation Coating Deposition Technology at MD&M West Show in Anaheim, California
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):